1009 related articles for article (PubMed ID: 21827775)
1. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Sanacora G; Treccani G; Popoli M
Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
[TBL] [Abstract][Full Text] [Related]
2. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors.
Musazzi L; Treccani G; Mallei A; Popoli M
Biol Psychiatry; 2013 Jun; 73(12):1180-8. PubMed ID: 23273725
[TBL] [Abstract][Full Text] [Related]
3. Stress, glucocorticoids and glutamate release: effects of antidepressant drugs.
Musazzi L; Racagni G; Popoli M
Neurochem Int; 2011 Aug; 59(2):138-49. PubMed ID: 21689704
[TBL] [Abstract][Full Text] [Related]
4. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptors in the control of mood disorders.
Witkin JM; Marek GJ; Johnson BG; Schoepp DD
CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
Femenía T; Gómez-Galán M; Lindskog M; Magara S
Brain Res; 2012 Oct; 1476():58-70. PubMed ID: 22541166
[TBL] [Abstract][Full Text] [Related]
7. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Kendell SF; Krystal JH; Sanacora G
Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
[TBL] [Abstract][Full Text] [Related]
8. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
Pham TH; Gardier AM
Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
[TBL] [Abstract][Full Text] [Related]
9. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
10. Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders.
Ohgi Y; Futamura T; Hashimoto K
Curr Mol Med; 2015; 15(3):206-21. PubMed ID: 25817855
[TBL] [Abstract][Full Text] [Related]
11. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
12. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Duman RS; Sanacora G; Krystal JH
Neuron; 2019 Apr; 102(1):75-90. PubMed ID: 30946828
[TBL] [Abstract][Full Text] [Related]
13. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
[TBL] [Abstract][Full Text] [Related]
15. [Glutamatergic conception of mood disorders].
Permoda-Osip A; Rybakowski J
Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
[TBL] [Abstract][Full Text] [Related]
16. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests.
Andreasen JT; Gynther M; Rygaard A; Bøgelund T; Nielsen SD; Clausen RP; Mogensen J; Pickering DS
Neurosci Lett; 2013 Jun; 546():6-10. PubMed ID: 23643996
[TBL] [Abstract][Full Text] [Related]
17. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Li YF
Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
[TBL] [Abstract][Full Text] [Related]
18. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Machado-Vieira R; Manji HK; Zarate CA
Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
[TBL] [Abstract][Full Text] [Related]
19. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?
Sanacora G; Schatzberg AF
Neuropsychopharmacology; 2015 Jan; 40(2):259-67. PubMed ID: 25257213
[TBL] [Abstract][Full Text] [Related]
20. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
Huang YJ; Lane HY; Lin CH
Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
